He will continue to fight for more federal funding to combat opioids, including education, prevention, and treatment programs.

Andy Harris · Maryland · Republican

spending impact 0.86 specificity 0.77 extraction confidence 97%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Occurrences

...will continue to fight for more funds for education, prevention, and treatment programs.

Promises ongoing advocacy for more opioid-response funding.

ISSUES | Andyharris
campaign · campaign_site · model gpt-5.4-mini

Evidence

legacy_unverified · Source version not recorded · locator unknown

The homepage says the office is in the congressional primary blackout period through June 23, 2026, but that regular website updates and constituent services will continue. It also links a FY2027 Programmatic Appropriations Form and lists June 16, 2026 as the latest news item.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Current official site activity shows Harris is still engaged in appropriations-related work, but there is no opioid-specific funding action in the last three days; the promise remains unresolved.

unresolved same_term

Congressman Andy Harris |Representing the First District of Maryland
primary · model gpt-5.4-mini · confidence 65%

legacy_unverified · Source version not recorded · locator unknown

The committees page says Harris serves on the House Appropriations Committee and its Labor, Health and Human Services, Education, and Related Agencies subcommittee.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): He still sits on the committee that controls federal health spending, so the promise is still within his federal role, but this is context rather than proof of delivered opioid funding.

unresolved same_term

Committees | Congressman Andy Harris
secondary · model gpt-5.4-mini · confidence 82%

legacy_unverified · Source version not recorded · locator unknown

Harris's official committees page says he serves on House Appropriations and on the Labor, Health and Human Services, Education, and Related Agencies subcommittee.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Harris has a current appropriations role directly relevant to HHS opioid prevention, treatment, and research funding, but committee membership alone does not prove that he secured or advanced more opioid funding.

unresolved same_term

Committees | Congressman Andy Harris
secondary · model gpt-5.5 · confidence 86%

unverified · Source version 55172 · locator unknown

Harris's press-release index says he applauded an HHS award of $2,715,203 to Salisbury-based AKYSO Therapeutics LLC for research on a new opioid use disorder treatment.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): A federal HHS opioid-use-disorder research award reached Harris's district during the current term, but the official text says he applauded the award rather than showing that he requested, authored, or secured it.

partial same_term

Press Releases | Congressman Andy Harris
primary · model gpt-5.5 · confidence 78%

legacy_unverified · Source version not recorded · locator unknown

NIH says the HEAL Initiative is congressionally funded and works to improve prevention and treatment strategies for opioid misuse and addiction and pain management.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): This confirms ongoing federal opioid-related research funding in the relevant policy area, but it does not connect the funding to Harris's own actions in the current term.

unresolved same_term

HEAL Initiative | National Institutes of Health (NIH)
secondary · model gpt-5.5 · confidence 82%

legacy_unverified · Source version not recorded · locator unknown

NIH lists active HEAL funding opportunities for substance use disorder and overdose interventions, prevention, recovery services, implementation, and health services research.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The federal government continued to offer opioid and substance-use research funding opportunities as of June 2026, but the page does not identify Harris as advancing those funds.

unresolved same_term

HEAL Funding Opportunities | National Institutes of Health (NIH)
secondary · model gpt-5.5 · confidence 80%

legacy_unverified · Source version not recorded · locator unknown

SAMHSA's State Opioid Response NOFO listed $1,480,500,000 in anticipated available funding for opioid misuse, OUD, overdose, prevention, treatment, harm reduction, and recovery services.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): This is direct evidence of large federal funding for opioid prevention, treatment, and recovery programs during the relevant period, but it does not show a Harris-specific funding increase or legislative push.

partial same_term

State Opioid Response Grants | SAMHSA
secondary · model gpt-5.5 · confidence 84%

legacy_unverified · Source version not recorded · locator unknown

The enacted FY2024 Labor-HHS division funded substance abuse prevention at $236,879,000 and included opioid-related NIH transfer authority and State Opioid Response Grants language.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Congress enacted opioid- and substance-abuse-related funding and authorities in FY2024, but this source by itself does not establish Harris's support or role in increasing those funds.

partial same_term

Public Law 118-47, Further Consolidated Appropriations Act, 2024
secondary · model gpt-5.5 · confidence 78%

legacy_unverified · Source version not recorded · locator unknown

The Clerk records the House vote on H.Res.1102 for concurrence in the Senate amendment to H.R.2882 as passed, and records Harris, Republican of Maryland, voting Nay.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Harris voted against the final House vehicle for the FY2024 appropriations law that contained opioid- and substance-abuse-related funding, which weakens a finding that he delivered more opioid funding through that enacted bill.

never same_term

Office of the Clerk, U.S. House of Representatives, Roll Call 102
secondary · model gpt-5.5 · confidence 86%

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): partial. same_term

Federal opioid-related funding continued during Harris's current House term, including SAMHSA State Opioid Response funding, NIH HEAL-related opportunities, and an HHS opioid-use-disorder research award in his district. Harris also holds a relevant Appropriations and Labor-HHS subcommittee role. However, the evidence does not show that he authored, sponsored, requested, or materially secured increased opioid education, prevention, or treatment funding, and he voted against the FY2024 appropriations vehicle that contained opioid- and substance-abuse-related funding. The outcome therefore receives partial credit for relevant federal funding occurring in-office, but not full delivery because candidate-specific contribution is weak.

provider codex_cli · model gpt-5.5 · confidence 74%

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): unresolved. same_term

Harris remains in federal office and on the appropriations subcommittee that handles health spending, but the evidence does not show a specific opioid-funding increase, enacted measure, or even a clearly documented opioid-focused legislative push tied to this promise. That makes the claim still unresolved rather than delivered or failed.

provider codex_cli · model gpt-5.4-mini · confidence 76%